Blocking Nogo Receptor 1 Promotes Functional Regeneration after Spinal Cord Injury

A, Mezler M Moeller; AH, Mueller BK Meyer

doi:10.4172/2329-6895.1000128

Cited by 3 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several approaches have been investigated, and NgR1 was blocked with NEP1-40, an antagonist of Nogo-66, a soluble NgR1 or a functionblocking NgR1 antibody, resulting in partially increased sprouting of axonal fibers in the corticospinal tract (Cao et al, 2008;Li et al, 2004;Moeller et al, 2013). These proteins are administered by intrathecal administration and do not easily cross the blood-brain barrier (BBB), which limited their application in the treatment of nerve injury diseases.…”

Section: Introductionmentioning

confidence: 99%

A novel Nogo-66 receptor antagonist peptide promotes neurite regeneration in vitro

Sun

Dai

Liu

et al. 2016

Molecular and Cellular Neuroscience

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

A novel Nogo-66 receptor antagonist peptide promotes neurite regeneration in vitro

Sun

Dai

Liu

et al. 2016

Molecular and Cellular Neuroscience

View full text Add to dashboard Cite

“…As NgR1 is a common receptor for most of the molecules in the pathway, it would make a reasonable target for antibody treatment. One group had attempted to assess this with an antibody highly selective for NgR1 [53]. Unfortunately, this produced only modest increases in functional recovery.…”

Section: Obstacles To Developmentmentioning

confidence: 99%

Evaluating the effectiveness of anti-Nogo treatment in spinal cord injuries

et al. 2020

View full text Add to dashboard Cite

As humans, we cannot regenerate axons within the central nervous system (CNS), therefore, making any damage to it permanent. This leads to the loss of sensory and motor function below the site of injury and can be crippling to a person's health. Spontaneous recovery can occur from plastic changes, but it is minimal. The absence of regeneration is due to the inhibitory environment of the CNS as well as the inherent inability of CNS axons to form growth cones. Amongst many factors, one of the major inhibitory signals of the CNS environment is the myelin-associated Nogo pathway. Nogo-A, Nogo-B and Nogo-C (Nogo), stimulate the Nogo receptor, inhibiting neurite outgrowth by causing growth cones to collapse through activation of Rho Kinase (ROCK). Antibodies can be used to target this signalling pathway by binding to Nogo and thus promote the outgrowth of neuronal axons in the CNS. This use of anti-Nogo antibodies has been shown to upregulate CNS regeneration as well as drastically improve sensory and motor function in both rats and primates when coupled with adequate training. Here, we evaluate whether the experimental success of anti-Nogo at improving CNS regeneration can be carried over into the clinical setting to treat spinal cord injuries (SCI) and their symptoms successfully. Furthermore, we also discuss potential methods to improve the current treatment and any developmental obstacles.

show abstract